title: Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients.
abstract: T lymphoblastic lymphoma (T-LBL) is a rare type of lymphoma with a good prognosis with a remission rate of 85%. Patients can be completely cured or can relapse during or after a 2-year treatment. Relapses usually occur early after the remission of the acute phase. The median time of relapse is equal to 1 year, after the occurrence of complete remission (range 0.2-5.9 years) (Uyttebroeck et al., 2008). It can be assumed that patients may be treated longer than necessary with undue toxicity.The aim of our model was to investigate whether the duration of the maintenance therapy could be reduced without increasing the risk of relapses and to determine the minimum treatment duration that could be tested in a future clinical trial.We developed a mathematical model of virtual patients with T-LBL in order to obtain a proportion of virtual relapses close to the one observed in the real population of patients from the EuroLB database. Our simulations reproduced a 2-year follow-up required to study the onset of the disease, the treatment of the acute phase and the maintenance treatment phase.
authors.affiliation: Institut Camille Jordan, UMR, CNRS, University Lyon 1, Villeurbanne, France.
authors.forename: N
authors.initials: N
authors.lastname: Eymard
authors.affiliation: Institut Camille Jordan, UMR, CNRS, University Lyon 1, Villeurbanne, France.
authors.forename: V
authors.initials: V
authors.lastname: Volpert
authors.affiliation: Institut Camille Jordan, UMR, CNRS, University Lyon 1, Villeurbanne, France.
authors.forename: P
authors.initials: P
authors.lastname: Kurbatova
authors.affiliation: INRIA Team Dracula, INRIA Antenne Lyon la Doua 69603 Villeurbanne, France.
authors.forename: V
authors.initials: V
authors.lastname: Volpert
authors.affiliation: Institute of Mechanical Engineering Problems, Saint Petersburg, Russia.
authors.forename: N
authors.initials: N
authors.lastname: Bessonov
authors.affiliation: Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School The University of Manchester, Manchester, UK.
authors.forename: K
authors.initials: K
authors.lastname: Ogungbenro
authors.affiliation: Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School The University of Manchester, Manchester, UK.
authors.forename: L
authors.initials: L
authors.lastname: Aarons
authors.affiliation: University of Lyon 1, UMR, CNRS, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Janiaud
authors.affiliation: University of Lyon 1, UMR, CNRS, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Nony
authors.affiliation: Unité de Biostatistique et d'Evaluation des Thérapeutiques Centre Léon Bérard, Lyon, France.
authors.forename: A
authors.initials: A
authors.lastname: Bajard
authors.affiliation: Unité de Biostatistique et d'Evaluation des Thérapeutiques Centre Léon Bérard, Lyon, France.
authors.forename: S
authors.initials: S
authors.lastname: Chabaud
authors.affiliation: Institute of Hematology and Oncology Paediatrics, Hospices Civils de Lyon, University Claude Bernard Lyon I, Lyon, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Bertrand
authors.affiliation: Hospices Civils de Lyon, Centre d'Investigation Clinique, INSERM CIC1407, Lyon, France.
authors.forename: B
authors.initials: B
authors.lastname: Kassaï
authors.affiliation: Hospices Civils de Lyon, Centre d'Investigation Clinique, INSERM CIC1407, Lyon, France.
authors.forename: C
authors.initials: C
authors.lastname: Cornu
authors.affiliation: CHU Lyon, Service de Pharmacologie Clinique et Essais Thérapeutiques, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Nony
mesh_terms: D003198:Computer Simulation; D018450:Disease Progression; D006801:Humans; D008962:Models, Theoretical; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*